Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Esteghamati, Alireza ^a   Jamali, Arsia ^a   Khalilzadeh, Omid ^a,b   Noshad, Sina ^a   Khalili, Mohammad ^a   Zandieh, Ali ^a   Morteza, Afsaneh ^a   Nakhjavani, Manouchehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLIBENCLAMIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; DISEASE DURATION; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

EID: 78049343062     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-65     Document Type: Article

References (40)

1. Adiponectin, hepatocellular dysfunction and insulin sensitivity. A Lopez-Bermejo P Botas T Funahashi E Delgado S Kihara W Ricart JM Fernandez-Real, Clin Endocrinol (Oxf) 2004 60 2 256 263 10.1046/j.1365-2265.2004.01977.x 14725689
2. Serum aminotransferase concentration as evidence of hepatocellular damage. MC Kew, Lancet 2000 355 9204 591 592 10.1016/S0140-6736(99)00219-6 10696975
3. Determination of enzyme activities in serum for the detection of xenobiotic effects on the liver. E Keil, Exp Pathol 1990 39 3-4 157 164 2257920
4. Abnormal liver enzyme levels. The spectrum of causes. JL Herrera, Postgrad Med 1993 93 2 113 116 8094553
5. Alanine aminotransferase in clinical practice. A review. KE Sherman, Arch Intern Med 1991 151 2 260 265 10.1001/archinte.151.2.260 1992953
6. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. B Vozarova N Stefan RS Lindsay A Saremi RE Pratley C Bogardus PA Tataranni, Diabetes 2002 51 6 1889 1895 10.2337/diabetes.51.6.1889 12031978 (Pubitemid 34564303)
7. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. N Sattar O Scherbakova I Ford DS O'Reilly A Stanley E Forrest PW Macfarlane CJ Packard SM Cobbe J Shepherd, Diabetes 2004 53 11 2855 2860 10.2337/diabetes.53.11.2855 15504965
8. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. AJ Hanley K Williams A Festa LE Wagenknecht RB D'Agostino J Kempf B Zinman SM Haffner, Diabetes 2004 53 10 2623 2632 10.2337/diabetes.53.10.2623 15448093
9. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. N Nakanishi K Suzuki K Tatara, Diabetes Care 2004 27 6 1427 1432 10.2337/diacare.27.6.1427 15161799 (Pubitemid 38679993)
10. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JM Clark AM Diehl, JAMA 2003 289 22 3000 3004 10.1001/jama.289.22. 3000 12799409
11. The prevalence and etiology of elevated aminotransferase levels in the United States. JM Clark FL Brancati AM Diehl, Am J Gastroenterol 2003 98 5 960 967 10.1111/j.1572-0241.2003.07486.x 12809815
12. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. G Musso R Gambino S Bo B Uberti G Biroli G Pagano M Cassader, Diabetes Care 2008 31 3 562 568 10.2337/dc07-1526 18056890
13. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. LL Stein MH Dong R Loomba, Adv Ther 2009 26 10 893 907 10.1007/s12325-009-0072-z 19921118
14. Pathogenesis of non-alcoholic steatohepatitis: human data. J Edmison AJ McCullough, Clin Liver Dis 2007 11 1 75 104 ix 10.1016/j.cld.2007.02.011 17544973
15. Nonalcoholic fatty liver disease. P Angulo, N Engl J Med 2002 346 16 1221 1231 10.1056/NEJMra011775 11961152
16. Diagnosis and therapy of nonalcoholic steatohepatitis. DM Torres SA Harrison, Gastroenterology 2008 134 6 1682 1698 10.1053/j.gastro.2008.02.077 18471547
17. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 31 Suppl 1(1) 55 60 18165338
18. Optimal waist circumference cut-offs for the diagnosis of metabolic syndrome in Iranian adults: results of the third national survey of risk factors of non-communicable diseases (SuRFNCD-2007). A Esteghamati M Abbasi A Rashidi A Meysamie O Khalilzadeh M Haghazali F Asgari M Nakhjavani, Diabet Med 2009 26 7 745 746 10.1111/j.1464-5491.2009.02756.x 19573127
19. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. KG Alberti P Zimmet J Shaw, Diabet Med 2006 23 5 469 480 10.1111/j.1464-5491.2006.01858.x 16681555
20. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth, Ann Intern Med 1999 130 6 461 470 10075613
21. Evaluation of the Hitachi 704 automatic analyzer. EG Lentjes GA Harff ET Backer, Clin Chem 1987 33 11 2089 2092 3677384
22. Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes. IJ Hickman JP Whitehead JB Prins GA Macdonald, Diabetes Obes Metab 2007 9 3 438 440 10.1111/j.1463-1326. 2006.00604.x 17391173
23. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. G Forlani P Di Bonito E Mannucci B Capaldo S Genovese M Orrasch L Scaldaferri P Di Bartolo P Melandri A Dei Cas,, et al. J Endocrinol Invest 2008 31 2 146 152 18362506
24. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. P Mofrad MJ Contos M Haque C Sargeant RA Fisher VA Luketic RK Sterling ML Shiffman RT Stravitz AJ Sanyal, Hepatology 2003 37 6 1286 1292 10.1053/jhep.2003.50229 12774006
25. Pathogenesis of steatohepatitis. CP Day, Best Pract Res Clin Gastroenterol 2002 16 5 663 678 10.1053/bega.2002.0333 12406438
26. Association of liver enzymes with incident type 2 diabetes: A nested case control study in an Iranian population. M Tohidi H Harati F Hadaegh Y Mehrabi F Azizi, BMC Endocr Disord 2008 8 5 5 10.1186/1472-6823-8-5 18533046
27. Lipotoxic diseases. RH Unger, Annu Rev Med 2002 53 319 336 10.1146/annurev.med.53.082901.104057 11818477
28. Non-alcoholic steatohepatitis: definitions and pathogenesis. CP Day S Saksena, J Gastroenterol Hepatol 2002 17 Suppl 3(3) 377 384 10.1046/j.1440-1746. 17.s3.31.x 12472967
29. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. G Marchesini M Brizi G Bianchi S Tomassetti E Bugianesi M Lenzi AJ McCullough S Natale G Forlani N Melchionda, Diabetes 2001 50 8 1844 1850 10.2337/diabetes.50. 8.1844 11473047
30. Nonalcoholic fatty liver disease. LA Adams P Angulo L KD, CMAJ 2005 172 899 905 15795412
31. Steatosis in donor and transplant liver biopsies. H Crowley WD Lewis F Gordon R Jenkins U Khettry, Hum Pathol 2000 31 10 1209 1213 10.1053/hupa.2000. 18473 11070113
32. Non-invasive means of measuring hepatic fat content. SR Mehta EL Thomas JD Bell DG Johnston SD Taylor-Robinson, World J Gastroenterol 2008 14 22 3476 3483 10.3748/wjg.14.3476 18567074
33. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. JE Jacobs BA Birnbaum MA Shapiro CP Langlotz F Slosman SE Rubesin SC Horii, AJR Am J Roentgenol 1998 171 3 659 664 9725292
34. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. RJ Johnston ER Stamm JM Lewin RE Hendrick PG Archer, Abdom Imaging 1998 23 4 409 415 10.1007/s002619900370 9663278
35. Fast spin-echo triple-echo dixon (fTED) technique for efficient T2-weighted water and fat imaging. J Ma JB Son Y Zhou H Le-Petross H Choi, Magn Reson Med 2007 58 1 103 109 10.1002/mrm.21268 17659631
36. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques - initial experience. A Qayyum JS Goh S Kakar BM Yeh RB Merriman FV Coakley, Radiology 2005 237 2 507 511 10.1148/radiol.2372040539 16244259
37. Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system. F Pilleul G Chave J Dumortier JY Scoazec PJ Valette, Gastroenterol Clin Biol 2005 29 11 1143 1147 10.1016/S0399-8320(05)82179-7 16505760
38. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. SS Lee SH Park HJ Kim SY Kim MY Kim DY Kim DJ Suh KM Kim MH Bae JY Lee,, et al. J Hepatol 52 4 579 585 10.1016/j.jhep.2010.01.008 20185194
39. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. R Longo P Pollesello C Ricci F Masutti BJ Kvam L Bercich LS Croce P Grigolato S Paoletti B de Bernard,, et al. J Magn Reson Imaging 1995 5 3 281 285 10.1002/jmri.1880050311 7633104
40. Quantification of liver fat using magnetic resonance spectroscopy. C Thomsen U Becker K Winkler P Christoffersen M Jensen O Henriksen, Magn Reson Imaging 1994 12 3 487 495 10.1016/0730-725X(94)92543-7 8007779